#Pulmonology Devices Therapies | Explore Tumblr posts and blogs

newsinsights · 3 years ago

Text

North America is the leading revenue contributor in the Global Pulmonology Devices Market

A recent market study published by Future Market Insights (FMI) on the pulmonology devices market offers global industry analysis for 2015-2019 & opportunity assessment for 2020-2030. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the pulmonology devices market, growth prospects of the market are obtained with maximum precision. The report features unique and salient factors that may make a huge impact on the development of the pulmonology devices market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in the pulmonology devices market in the coming years. The report provides detailed information about the current and future growth prospects of the pulmonology devices market in the most comprehensive way for better understanding of readers.

Key Segments of Pulmonology Devices Market

FMI’s study on the pulmonology devices market offers information divided into four important segments - product, indication, end user and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

Pulmonary Biopsy Devices

Endobronchial Ultrasound (EBUS) Needles

Airway Stents

Airway Extraction Baskets

Single-Use Bronchoscopes

Single- Use Biopsy Forceps

Cytology Brushes

Microbiology Brushes

Endobronchial Ultrasound Fine Biopsy Needles

Endobronchial Ultrasound Transbronchial Aspiration Needles

Silicon Stents

Nitinol Stents

Stainless Steel Stents

Indication

Lung Cancer

COPD

Foreign Body Extraction

Tracheal and Bronchial Stenosis

Others

End User

Hospitals

Pulmonology Clinics

Ambulatory Surgical Centers

Region

North America

Latin America

Europe

East Asia

South Asia

Oceania

MEA

Request For Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-13036

Chapter 1 – Executive Summary

The report commences with the executive summary of the pulmonology devices market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the pulmonology devices market as well as the key trends impacting the market.

Chapter 2 – Market Overview

Readers can find detailed taxonomy and product definition of the pulmonology devices market, in this chapter, which help readers understand basic information about pulmonology devices.

Chapter 3 – Key Market Trends

This section highlights the key trends impacting the pulmonology devices market, which will help readers understand the current trends and their impact on market growth.

Chapter 4 – Market Background

This chapter explains the key macroeconomic factors that are expected to influence the growth of the pulmonology devices market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the pulmonology devices market, which include the drivers, restraints, and opportunity analysis. This chapter is expected to enable readers to understand the factors that are propelling the growth of the pulmonology devices market, as well as those that are likely to hamper the growth of the pulmonology devices market. The opportunity analysis for the pulmonology devices will help readers understand the market opportunities, based on which they can plan their strategies.

Chapter 5 – Key Success Factors

This chapter explains the key regulations for product launch in various countries along with regulatory scenario that are expected to influence the growth of the pulmonology devices market during the forecast period

Chapter 6 – COVID19 Crisis Analysis

This section provides the current and expected impact of COVID19 on the pulmonology devices market.

Chapter 7 – Global Pulmonology devices Market Volume (Units) Analysis 2015-2019 and Forecast 2020-2030

This section explains the global market volume analysis and forecast for the pulmonology devices market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2020–2030).

Chapter 8 – Global Pulmonology devices Market – Pricing Analysis

This section explains the global market pricing of the product in key regions and forecast for the pricing in pulmonology devices market during the forecast period

Chapter 9 – Global Pulmonology devices Market Value (US$) Analysis 2015-2019 and Forecast 2020-2030

This section explains the global market value analysis and forecast for the pulmonology devices market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2020), and an incremental $ opportunity for the forecast period (2020–2030).

Chapter 10 – Global Pulmonology devices Market Analysis (2015-2019) & Opportunity Assessment (2020-2030), By Product

Based on Product, the pulmonology devices market is segmented into pulmonary biopsy devices, endobranchial ultrasound (EBUS) needles, airway stents, airway extraction baskets, and single-use bronchoscopes. In this chapter, readers can find information about a detailed analysis of the market by different product of pulmonology devices and their growth over the forecast period.

Chapter 11 – Global Pulmonology devices Market Analysis 2015-2019 & Opportunity Assessment, 2020-2030, By Indication

Based on Indication, the pulmonology devices market is segmented into Lung Cancer, COPD, Foreign Body Extraction, Tracheal and Bronchial Stenosis, and others. In this chapter, readers can find information on market attractive analysis based on Application.

Chapter 12 – Global Pulmonology devices Market Analysis 2015-2019 & Opportunity Assessment, 2020-2030, By End User

Based on End User, the pulmonology devices market is segmented into hospitals, pulmonology clinics, and ambulatory surgical centers. In this chapter, readers can find information on market attractive analysis based on End User

Chapter 13 – Global Pulmonology devices Market Analysis 2015-2019 & Opportunity Assessment 2020-2030, By Region

This chapter explains how the pulmonology devices market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania and MEA.

The Pulmonology Devices market research gets rid of the following queries:

How the market for Pulmonology Devices is expected to shape in the coming ten years?

What strategies are the Pulmonology Devices market vendors implementing to stay ahead of their rivals?

Why are consumers shifting towards alternative Pulmonology Devices products?

What innovative technologies are the Pulmonology Devices players using to get an edge over their rivals?

What are the restraints affecting the growth of the global Pulmonology Devices market?

Any Queries, Contact Us @ https://www.futuremarketinsights.com/ask-question/rep-gb-13036

Reasons to Buy the report

We provide authentic and detailed an analysis on various market trends to enable businesses to make informed and beneficial decisions to attain competitive edge over key players.

Our analysts provide detailed market segmentation along with meaningful insights and extensive reports that other companies fail to include.

The report includes accurate analysis of the market and the current developing trends affecting the growth. FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. This ensures that the data collected is from highly reliable sources.

Why Future Market Insights?

Comprehensive analysis on evolving purchase pattern across different geographies

Detailed insights of market segments and sub-segments for historical as well as forecast period

A competitive analysis of prominent players and emerging players in the Pulmonology Devices market

Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Explore Wide-ranging Coverage of FMI’s Healthcare Market Insights Landscape

Surface Plasmon Resonance Market - 2019 Analysis and Review of Surface Plasmon Resonance Market by Product Type - Imaging Systems, Sensor Systems, and Reagents for 2019 - 2029

Neuroendocrine Carcinoma Treatment Market - 2019 Analysis and Review of Neuroendocrine Carcinoma Treatment Market by Treatment Type - Somatostatin Analogs, Targeted Therapy, and Chemotherapy for 2019 - 2029

Plant Derived Proteins Market - 2019 Analysis and Review of Plant Derived Proteins Market by Protein - Industrial Proteins & Enzymes, Therapeutic Proteins, Cell Culture Functional Proteins, and Others for 2019 - 2029

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai,

United Arab Emirates

MARKET ACCESS DMCC Initiative

For Sales Enquiries: [email protected]

For Media Enquiries: [email protected]

#Pulmonology Devices Market

0 notes

columbia-asia-india · 5 years ago

Photo

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease describes a spectrum of chronic inflammatory lung diseases that block the airflow to the lungs and makes breathing difficult. It is caused due to long-term exposure to irritating gases and particulate matter suspended in the air, usually cigarette smoke, and hampers normal breathing. It is irreversible and progressive in nature. However, it can be controlled by prompt medical care. Columbia Asia is one of the best pulmonology hospitals in Bangalore which possesses the required facilities and technical expertise to treat such diseases.

CAUSES

All types of COPD are caused due to airborne irritants.The common causes are:

Smoking: About 80 to 90 percent of all the cases of COPD are caused due to smoking, although non-smokers who’ve had prolonged exposure to second-hand smoke are also likely to get this disease.

Exposure to chemicals and fumes in the workplace, such as cadmium dust, grain and flour dust, welding fumes and coal dust.

Fumes from burning fuel used for cooking and heating, which is more likely in developing countries.

Respiratory infections

Indoor air pollution

In a small percentage of cases, it might be due to genetic factors such as deficiency in alpha-1-antitrypsin protein which causes deterioration of the lung function.

If you observe that your surroundings are conducive to such factors, it might be a good idea to get yourself medically checked periodically. Columbia Asia hospitals are premier lung disease treatment centre in Bangalore that is clinically equipped to conduct such type of health checks.

SYMPTOMS OF COPD

The symptoms don’t usually manifest until the disease is in its advanced stages and there has been considerable damage to the lungs. Some of the early symptoms of COPD are:

Persistent, mild cough with the production of mucus

Wheezing

Shortness of breath

Chest tightness

Fatigue

One needs to be particularly observant with regard to the symptoms and seek appropriate care if he/she lives in cities infamous for their pollution levels. Columbia Asia is reputed for its asthma treatment in Bangalore and is at the forefront of the fight against such type of lung diseases.

DIAGNOSIS

A physical examination is performed to look for any visible signs of COPD, such as cyanosis. The tests performed to assess the lung function include:

Spirometry: A device called spirometer is used to measure the amount of air that a person can breathe in and out and check if the lungs are supplying the blood with sufficient oxygen.

Imaging Tests: Chest X-rays and CT scan provide a detailed image of the lungs, heart and the blood vessels. A CT scan also helps detect emphysema.

Arterial blood gas test: A sample of the blood is taken from an artery to measure the levels of oxygen and carbon dioxide in the blood.

Exercise Tolerance Test: This evaluates the impact of exercise on the ability of the heart and lungs to bring in oxygen and expel carbon dioxide from the bloodstream.

Bronchial Provocation Test: This test is done very rarely. In this, the patient undergoes spirometry after inhaling a specific drug such as methocholine or histamine to assess the sensitivity of the lungs.

Peak flow test: This is a breathing test which determines how fast a person can exhale and is helpful in ruling out asthma.

How is COPD treated?

COPD doesn’t have a cure as yet, and hence the treatment options focus on slowing down the rate of progression of this disease, relieving the symptoms and improving the quality of life through adequate lifestyle modifications. Columbia Asia is among the top COPD treatment centers in Bangalore and provides many treatment alternatives to combat this condition.

Cease to smoke: This is the most important and highly mandatory step in the treatment plan for COPD.

Oxygen Therapy: In order to enhance the oxygen levels in the blood, supplemental oxygen can be given through a portable mask to help the person breathe better. It increases the survival rates in the patients and improves the quality of life.

Pulmonary Rehabilitation: This includes a mix of exercise, education and psychological support to help patients with debilitating symptoms and should be carried out for a long enough time to provide optimum benefits.

Medications: There are a variety of medicines available such as broncodilators, corticosteroids, antibiotics etc. which focus on reducing the inflammation of the airways and mucus production to ease the breathing.

Surgery: Lung volume reduction surgery and lung transplant are the surgical options for treating this disease.

Lifestyle modifications such as following a healthy diet plan, doing yoga etc. also have beneficial effects on the patients.

#best pulmonology hospital in Bangalore #copd treatment in Bangalore #lung disease treatment in Bangalore #asthma treatment in Bangalore #chronic obstructive pulmonary disease

0 notes

oanda-pp · 6 years ago

Text

Pink Himalayan Salt Is a Waste of Money

Sure it looks nice, but claims that it’s cleaner and more nutritious than regular salt are dubious at best.

Zoran Djekic / Stocksy

Right around January 1 the past few years, Google searches for “pink Himalayan salt” spike like your blood pressure after consuming a bucket of French fries. To become a better, healthier version of yourself, apparently, you absolutely must switch to using luscious pink-tinged salt crystals instead of those factory-refined white grains. Or so wellness experts and influencers might lead us to believe—and lots of us probably want to believe so we can feel less bad about craving salt.

While all trendy foods have hyperbole built into their marketing (looking at you, bone broth aka expensive meat tea) pink Himalayan salt might take the cake: Yes, it costs more, but it’s natural, unrefined salt with dozens of minerals and elements that’s extracted by hand from mines untouched by pollution! And it looks nice!

As Amanda Mull recently wrote in The Atlantic, we can attribute pink salt’s popularity to its pleasing appearance combined with trendy concepts of wellness in which “single foods or ingredients end up with a vague reputation for quasi-medicinality, often based on notions of their purity or naturalness.”

OK fine, but is pink salt healthier than regular table salt?

The wellness claims about pink salt range from dumb to dangerous. Dr. Axe says pink Himalayan salt is “cleaner” and more nutritious than regular salt. His site even swears it’s a natural sleep inducer. GOOP promises its $40 Pink Himalayan Salt Scrub will “detoxify” your skin. SoWell.com swears breathing pink salt-ified air will cure your asthma—and conveniently sells the inhaler pipe that will deliver your respiratory salvation. And finally, there’s this mumbo-jumbo over on HimalayanCrystalSalt.com about a 2007 study using an Optimized Wellness Analyzer to evaluate pink salt’s effect on “wellness” versus a placebo. Surprise: The pink salt group scored healthier when evaluated by the wellness analyzer. Less of a surprise: I couldn’t find the study on PubMed or Google Scholar, and the website doesn’t cite which peer-reviewed journal the study was published in.

If any of these claims are valid(ish), it’s that pink salt may have more minerals than purified white salt—but it’s a drop in the bucket. “Himalayan salt does contain trace amounts of minerals like potassium, magnesium, iron, and more, but the amounts are insignificant and afford no additional health benefits,” says Jeff McGrath, a clinical dietitian at Westchester Medical Center, the university hospital of New York Medical College. And as long as you’re eating a healthy, balanced diet, you’re probably not in need of these elements, McGrath says. (In case you’re wondering where the salt’s rosy hue comes from, it probably comes from “Iron oxide, AKA rust,” says Catherine Brennan, a Rhode Island-based registered dietitian. Yum.)

Speaking of its nutritional value, pink Himalayan salt usually doesn’t contain significant amounts of iodine, which is an essential nutrient, Brennan says. While iodine deficiencies are uncommon in the United States (thanks to salt with iodine added, aka iodized salt), it’s a real problem around the globe. “Iodine’s main function is as an important component of thyroid hormones,” Brennan says.“Persons deficient in iodine cannot make enough thyroid hormone, which can lead to hypothyroidism, or even enlargement of the thyroid—known as goiter."

And, “Ironically, Himalayan pink salt also contains barely detectable amounts of elements that would be harmful if isolated and consumed in large doses, such as arsenic and uranium,” McGrath says.

Claims that Himalayan salt is somehow more natural or pure than regular table salt are hard to verify—and may not really matter. “In the current food world, the term ‘natural’ means very little,” Brennan says. Yes, white salt is cleaned, heated, and treated with anti-caking agents, she explains, but sometimes a little bit of scrubbing can be a good thing. “Depending on the source, pink salt may contain some harmful trace minerals such as lead.”

If you want to keep buying pink Himalayan salt, that’s fine—just know that it’s not any better for you than boring, old white salt. And sorry not sorry: Pink Himalayan salt-laced potato chips, popcorn, and chocolate bars are not health foods.

But please, please, please don’t drink Himalayan salt mixed with a glass of water each morning the way some health and lifestyle bloggers and salt companiesurge you to. While that’s a great way to sell salt, “The American diet tends to provide significantly more sodium than is required,” McGrath says, adding that “excess sodium intake contributes to high blood pressure, which can eventually cause strokes and lead to heart and kidney failure.”

What about that stuff about pink salt helping you breathe better?

Don’t expect pink salt lamps or salt rooms to cure your asthma either. “In Eastern Europe and Russia, people have been descending into salt caves to treat respiratory diseases, but we don’t have very much rigorous data on it,” says Maureen George, an associate professor at Columbia University’s School of Nursing. “If the air contains microscopic salt crystals, that can cause a change in the mucus in the lungs and can cause coughing, which some find worsen their asthma, but some find it makes them feel better,” she says. Still, any results would be temporary.

There is one study, published in Pediatric Pulmonology in 2016, that found children’s asthma did improve directly after a “halotherapy” session, aka time spent in a salt room. However, George points out that the study only used children with asthma so moderate they didn’t need daily inhaler treatment, and that the results were measured only right after the session. “It’s a small signal that immediately after the artificial salt room therapy that kids in this trial had better quality of life scores and less airway twitchiness,” she says, but, “we don’t have any long-term, rigorously designed studies or large, randomized studies.”

Furthermore, to get the better-breathing benefits, you’d need the salt particles to be in the air—and a nightstand salt lamp definitely isn’t going to produce that result.

Still, if you want to go sit in a salt room to meditate, George isn’t going to stop you. “I’m a scientist, but I’m really into letting people do what works for them, and we know that mind-body interventions can be a powerful tool” she says. Just don’t stop using your asthma meds without consulting your physician.

Finally, the pink salt inhalers are likely useless for asthma treatment. “The device they’re using is not FDA-approved and looks like something that would only impact the upper respiratory tract. It’s what would land in your nose and mouth,” George explains. Getting medicine deep into your lungs—where it’s actually going to help you—is pretty tricky. “The tech in asthma inhalers is really complicated. It’s all about particle size and carriers.”

Anything else I need to know?

Most of these pink Himalayan salt remedies aren’t going to hurt you (minus the daily saltwater-chugging routine, that is not good). But overpaying for seasonings and snacks and shelling out $40 for a useless product smarts. And trust us, no matter what GOOP tells you, rubbing salt in the wound—even if it’s pink and (kinda) from the Himalayas—won’t help.

Oh yeah, and only kinda from the Himalayas. Banish those images of gorgeous pink salt mountain cliffs rising into the clouds in the world’s highest mountain range: Most pink Himalayan salt actually comes from a Pakistani government-owned mine that’s south of the famed mountains. The Khewra Salt Mine is now a tourist attraction, but its history is violent. During British colonial rule, the British forced locals to work in slave-like conditions in the mine. Even today, wages are low. Pakistani newspaper The Dawn reported in 2018 that a miner makes 350 Pakistani rupees, or about $2.50, for every ton of salt excavated. Think about that the next time you spend $5.99 for four ounces of the stuff on Amazon.

This article originally appeared on Tonic.

0 notes

peertechz · 7 years ago

Link

0 notes

greatestlcve · 4 years ago

Text

Seretide drug Uses, Dosage, Side Effects, Precautions & Warnings

Drug Online

seretide drug class >>Generic drug of the therapeutic class: Pulmonology active ingredients: Fluticasone , Salmeterol

Important to know about Seretide ?

Asthma.

You must use Seretide every day as directed by your doctor. This will properly control your asthma.

Seretide prevents the occurrence of shortness and hissing. It does not work when you already have a shortness of breath or hissing sound. In these cases, you should use your fast-acting, short-acting bronchodilator, such as salbutamol.

What is Seretide used for and indication ?

What is Seretide used for

Seretide and Seretide Diskus:

Asthma:

Continuous treatment of asthma, in situations where the inhaled administration of a combination corticosteroid and long-acting ß-2 agonist bronchodilator is warranted:

in patients inadequately controlled by inhaled corticosteroid therapy and a short-acting ß-2 agonist bronchodilator by inhalation “on demand”, or

in patients controlled by the administration of inhaled corticosteroids associated with continuous therapy with inhaled long-acting ß-2 agonist.

Note :

Seretide Inhalation Suspension 50 μg / 25 μg / dose and Seretide Diskus 100 μg / 50 μg / dose are not suitable for the treatment of severe adult and pediatric asthma.

Seretide Diskus at 500 μg / 50 μg / dose:

Chronic Obstructive Pulmonary Disease (COPD):

Symptomatic treatment of COPD in patients whose FEV1 (measured before bronchodilator administration) is less than 60% of the theoretical value, and who has a history of repeated exacerbations and significant symptoms despite continuous bronchodilator therapy.

seretide dosage 250/50/25

Inhaled route only.

The patient should be informed that to observe an optimal treatment effect, Seretide should be administered daily even when symptoms are improved.

The doctor should regularly check that the prescribed dosage of Seretide is well adapted to the clinical condition of the patient. It will only be changed with medical advice.

The minimum effective dosage should always be sought. When symptoms are controlled by the lowest recommended dose twice daily, then inhaled corticosteroid alone will be considered.

It may also be considered to reduce the dosage of Seretide once a day, if the physician considers it necessary to maintain a long-acting beta-2 mimetic treatment for symptom control.

The time of taking Seretide will then depend on the frequency of appearance of symptoms. If the predominance of symptoms is nocturnal, Seretide will be given in the evening; if it is diurnal,

The dosage of Seretide that will be prescribed to the patient should correspond to the dose of fluticasone propionate adapted to the severity of his asthma. It should be emphasized that Seretide 50 micrograms / 25 micrograms / dose is not suitable for the treatment of severe adult and pediatric asthma. In asthmatics, fluticasone propionate (FP) is as effective as other inhaled corticosteroids at approximately half the daily dose. For example, administered by inhalation, 100 micrograms of fluticasone propionate are approximately equivalent to 200 micrograms of beclometasone dipropionate (BDP) (CFC formulation) or budesonide.

Recommended dosage:

Asthma

seretide dosage Adults and Teens 12 years and older:

Two inhalations of 50 μg of fluticasone propionate and 25 μg of salmeterol twice daily..or

Two inhalations of 125 μg fluticasone propionate and 25 μg salmeterol 2 times daily..or

Two inhalations of 250 μg of fluticasone propionate and 25 μg of salmeterol twice daily..or

Seretide may be considered as an initiation therapy for a short trial period in adults and adolescents with moderate persistent asthma (defined by the presence of daytime symptoms, daily use of a short-term bronchodilator).

action in symptomatic relief treatment and moderate to severe bronchial obstruction) and in whom it appears essential to obtain a rapid control of asthma. In these cases, the recommended initial dose is two inhalations of 25 micrograms of salmeterol and 50 micrograms of fluticasone propionate, twice daily.

When control of asthma is achieved, treatment should be re-evaluated to consider reducing treatment to inhaled corticosteroid alone. It is important that patients are followed regularly during the treatment reduction period.

There is no clear benefit of Seretide for initiation therapy compared with fluticasone propionate inhaled alone when 1 to 2 of the severity criteria discussed above are not present. In the majority of cases, the first-line treatment remains the administration of inhaled corticosteroids alone. Seretide is not intended for first-line treatment of mild asthma. The 50 microgram / 25 microgram Seretide is not suitable for adults and children with severe asthma; the appropriate dose of inhaled corticosteroids should be adjusted individually before

Children 4 years old and over:

Two inhalations of 50 μg of fluticasone propionate and 25 μg of salmeterol twice daily.

In children, the recommended maximum dose of inhaled fluticasone propionate is 100 micrograms twice daily.

No data are available on the use of Seretide in children under 4 years of age.

Children under 12 may have difficulty coordinating the triggering of the inhalation device with their inspiration. The use of an inhalation chamber with Seretide suspension for inhalation in a pressurized bottle is recommended in patients who have or may have difficulty coordinating their inspiration with the triggering of the inhalation device. A recent clinical study showed that pediatric patients who used an inhalation chamber had similar exposure to adults who did not use an inhalation chamber and pediatric patients who had used a Diskus device. confirming that the inhalation chamber compensates for a poor technique of

Volumatic or AeroChamber Plus inhalation chambers can be used. Limited data has shown increased systemic exposure when inhaled using the AeroChamber Plus inhalation chamber compared to the Volumatic inhalation chamber (see Warnings and Precautions section ). .

Patients should be informed of the procedures for the use and maintenance of their inhalation device and their inhalation chamber. It should also be checked that the patient is using the inhalation chamber properly so that the product is delivered optimally to the lung. Whenever possible, patients should continue to use the same type of inhalation chamber, as switching from one chamber to another may vary the dose of inhaled product (see Warnings and Precautions section). employment ). When introducing or changing the inhalation chamber, the minimum effective dose should always be sought.

Populations at risk:

There is no need to adjust doses in elderly or renally impaired patients. No data are available on the use of Seretide in patients with hepatic impairment.

Contraindications

Salmeterol hypersensitivity

Fluticasone hypersensitivity

Norflurane hypersensitivity

Feeding with milk

Pregnancy

Hypersensitivity to the active substances or to any of the excipients listed in the Composition section.

seretide how to use

Patients should be informed about how the metered dose inhaler works (see leaflet).

During inhalation, the patient should preferably sit or stand. The aerosol has been designed for use in a vertical position.

Verification of the operation of the device:

Before first use, in order to check the proper functioning of the device, release puffs of product in the air until the meter indicates 120 doses. For this, after having removed the cap of the mouthpiece by exerting a pressure on each side, shake the inhaler well, hold the device between the fingers by positioning the thumb at the base of the device under the mouthpiece, then press on the cartridge. Shake the device right before activating to release each puff. If the device has not been used for a week or more, remove the cap from the mouthpiece, the patient should shake the inhaler and release two puffs of product into the air. The number of doses released is counted each time the device is triggered.

Use of the aerosol:

The patient should remove the cap from the mouthpiece by exerting pressure on each side.

The patient should check that there is no foreign body inside or outside the device, including the mouthpiece, to ensure that it is clean.

The patient should shake the aerosol well to remove any foreign matter and ensure mixing of the suspension components in the vial.

The patient should hold the aerosol straight between the fingers and thumb with his thumb at the base, under the mouthpiece.

The patient should exhale as much as possible then place the mouthpiece in his mouth between the teeth and close the lips around. Tell the patient that they should not bite the mouthpiece.

Right after starting to inhale through the device through the device, the patient should firmly press down on the top of the metered dose inhaler to release the product, while inhaling regularly and deeply.

While holding his breath, the patient will remove the inhaler from his mouth. The patient will hold his breath as much as possible.

If the patient is to take a second inhalation, he / she should keep the MDI straight and wait about 30 seconds before repeating steps 3 to 7.

The patient should replace the cap on the mouthpiece immediately afterwards by firmly pressing the cap, making sure that it is in the correct position .. There is no need to exert a significant force to replace the cap on the mouthpiece, a simple “click” is enough to ensure the closure of the mouthpiece by the cap.

IMPORTANT

Steps 5, 6 and 7 should not be performed in a hurry. It is important for the patient to start breathing as slowly as possible before triggering the device. The patient will have to train the first time in front of a mirror. If he sees a bit of “smoke” coming out of the top of the metered dose inhaler or at the corner of his mouth, he must start again from step 2.

Patients should consider replacing the metered dose inhaler when the dose counter reads 020. When all available doses in the device have been dispensed, the meter displays 000. The metered aerosol must be replaced when the meter reads 000 .

Patients should never try to change the numbers on the meter or detach it from the metal cartridge. The counter can not be reset and remains permanently attached to the cartridge.

Cleaning :

The device should be cleaned at least once a week.

Remove the cap from the mouthpiece.

Do not remove the cartridge from its plastic adapter.

Wipe the inside and outside of the mouthpiece and plastic adapter with a clean, dry tissue or tissue.

Replace the mouthpiece cap, making sure that it is correctly positioned in the correct direction. There is no need to exert a significant force to replace the cap on the mouthpiece, a simple “click” is enough to ensure the closure of the mouthpiece by the cap.

DO NOT PUT THE METAL CARTRIDGE IN WATER.

how does seretide works

Pharmacotherapeutic group: Adrenergic and other drugs for obstructive airways syndromes

ATC Code: R03AK06

Clinical studies conducted with the propionate combination of fluticasone / salmeterol in asthma:

A 12-month study (Gaining Optimal Asthma controL, GOAL) in 3416 adult and adolescent patients with persistent asthma compared the safety and efficacy of Seretide with inhaled corticosteroid alone (fluticasone propionate) to evaluate the possibility of achieving the goals of asthma management. The dosage of treatment was increased every 12 weeks until full control ** was obtained or the highest dose in the study was reached. GOAL showed that there were more patients achieving asthma control when treated with Seretide than with inhaled corticosteroids alone, with lower doses of corticosteroids.

“Good Control” of asthma was achieved more rapidly in patients treated with Seretide than in patients treated with inhaled corticosteroids alone. The time required for 50% of subjects in the study to reach their first week of “good control” was 16 days for subjects treated with Seretide and 37 days for those treated with inhaled corticosteroids (ICS). In the subgroup of asthmatic patients not previously treated with inhaled corticosteroids, this time was 16 days (Seretide) and 23 days (CSI), respectively.

The overall results of the study were as follows:

Percentage of patients achieving * Good Control (BC) and ** Total Control (CT) of asthma over 12 months

Treatment before inclusion in the study

FP 4 / Salmeterol

FP 4

No CSI 1 (ß2 CDA 2 alone)

78%

50%

70%

40%

Low dose ICS (≤ 500 μg BDP 3 or equivalent per day)

75%

44%

60%

28%

Medium dose ICS (> 500-1000 μg BDP 3 or equivalent per day)

62%

29%

47%

16%

Overall results (regardless of previous treatment)

71%

41%

59%

28%

CSI: inhaled corticosteroids

ß2 CDA: Beta-2 short-acting agonist

BDP: beclometasone dipropionate

FP: Fluticasone Propionate

* Good asthma control: occasional symptoms or occasional use of a short-acting beta-2 agonist bronchodilator, or pulmonary function less than 80% of the theoretical values, without nocturnal awakening, exacerbation or adverse effect a modification of treatment.

** Total control of asthma: no symptoms, no use of a short-acting beta-2 agonist bronchodilator, pulmonary function greater than or equal to 80% of the theoretical values, no nocturnal awakening, no exacerbation no adverse effect leading to a change in treatment.

The results of this study suggest that Seretide 100 micrograms / 50 micrograms / dose, twice a day, may be considered for initiation of DMARD therapy in patients with moderate persistent asthma who experience essential control. asthma (see Dosage and administration section ).

Une étude en double aveugle, randomisée en groupes parallèles, conduite chez 318 patients d’au moins 18 ans, atteints d’asthme persistant, a évalué la sécurité et la tolérance de l’administration de deux inhalations deux fois par jour (double dose) de Seretide pendant deux semaines. Cette étude a montré que le doublement de la dose de Seretide (quel que soit le dosage), sur une durée allant jusqu’à 14 jours, entraîne par rapport à l’administration d’une inhalation deux fois par jour, une légère augmentation des effets indésirables liés à l’activité bêta-mimétique (tremblements : 1 patient [1 %] vs 0, palpitations : 6 [3 %] vs 1 [<1 %], crampes musculaires : 6 [3 %] vs 1 [<1 %]) et une incidence similaire des effets indésirables liés au corticoïde inhalé (candidose orale : 6 [6 %] vs 16 [8 %], raucité de la voix : 2 [2 %] vs 4 [2 %]). La faible augmentation des effets indésirables liés à l’activité bêta-mimétique doit être prise en considération, s’il est envisagé de doubler la dose prescrite de Seretide chez des patients adultes qui nécessiteraient une augmentation de la corticothérapie inhalée pendant une courte période (jusqu’à 14 jours).

Multicenter trial in asthma with salmeterol (“Salmeterol Multi-Center Asthma Research Trial, SMART”)

The SMART study was a multi-center, randomized, double-blind, parallel group, placebo-controlled study conducted in the United States over 28 weeks. 13176 patients received salmeterol (50 micrograms twice daily) and 13179 patients received placebo administered in addition to their usual anti-asthmatic treatment. To be included in the study, patients had to be at least 12 years old, be asthmatic and have ongoing anti-asthmatic treatment (excluding long-acting beta-2 agonist therapy). action). Inhaled corticosteroid therapy was not mandatory during the study, although the use of corticosteroids was nevertheless recorded at study entry. The main criterion of judgment of the

Results of the SMART study on the primary endpoint:

Patient groups

Main criterion:

Number of events /

number of patients

Relative risk

(95% Confidence Interval)

salmeterol

placebo

Overall population included

50/13176

36/13179

1.40 (0.91, 2.14)

Patients using inhaled corticosteroids

23/6127

19/6138

1.21 (0.66, 2.23)

Patients not using inhaled corticosteroids

27/7049

17/7041

1.60 (0.87, 2.93)

Subgroup of African-American patients

20/2366

5/2319

4.10 (1.54, 10.90) **

** statistically significant at 95%

Other results of the SMART study according to whether or not inhaled corticosteroids were taken at baseline:

Secondary criteria:

Number of events / number of patients

Relative risk

(95% Confidence Interval)

salmeterol

placebo

Number of deaths related to a respiratory cause

Patients using inhaled corticosteroids

10/6127

5/6138

2.01 (0.69, 5.86)

Patients not using inhaled corticosteroids

14/7049

6/7041

2.28 (0.88, 5.94)

Combined criterion combining asthma episodes that have led to death or life-threatening

Patients using inhaled corticosteroids

16/6127

13/6138

1.24 (0.60; 2.58)

Patients not using inhaled corticosteroids

21/7049

9/7041

2.39 (1.10, 5.22) **

Number of deaths related to asthma

Patients using inhaled corticosteroids

4/6127

3/6138

1.35 (0.30, 6.04)

Patients not using inhaled corticosteroids

9/7049

0/7041

* = relative risk could not be calculated due to no event in the placebo group.

** The results are statistically significant at 95%. The secondary criteria in the table above reached statistical significance in the entire study population.

The secondary criteria of “death or vital threats from all causes”, “all-cause death” or “all-cause hospitalization” did not reach statistical significance for the entire study population.

Action mechanism

Seretide contains salmeterol and fluticasone propionate which have different modes of action:

salmeterol

Salmeterol is a selective long-acting agonist (12 hours) for beta-2 adrenergic receptors. It has a long side chain that links it to the receiver’s exo-site.

Salmeterol produces bronchodilation which persists for about 12 hours. This duration is greater than that generally observed with short-acting beta-2 mimetics administered at the usual dosages.

Fluticasone propionate

Fluticasone propionate administered by the inhaled route at the recommended doses exerts a glucocorticoid activity causing a local anti-inflammatory effect at the level of the bronchial mucosa. As a result, asthma symptoms and exacerbations are reduced while systemic effects are limited compared to systemic corticosteroid use.

Does Seretide have side effects?

yes it’s and this’s Description of adverse effects

Like all medicines, SERETIDE 50 micrograms / 25 micrograms / dose, suspension for inhalation in a pressurized bottle can cause side effects, but they do not occur systematically in everyone.

To prevent the occurrence of side effects, your doctor will prescribe the lowest possible dose to control your asthma.

Allergic Reactions: You may find that your breathlessness worsens suddenly after you use Seretide. You can perceive bronchial wheezing and coughing. You may also experience itching and swelling (usually on the face, lips, tongue, or throat). If you experience these symptoms or if they suddenly appear after using Seretide, tell your doctor immediately. Allergic reactions to Seretide are very rare (they affect less than 1 in 10,000 people).

Other side effects are described below:

Very common effects (affects more than 1 in 10 people):

· Headache usually decreases with further treatment.

· An increase in colds has been reported in patients with Chronic Obstructive Pulmonary Disease (COPD) treated with Seretide.

Common effects (affect less than 1 in 10 people):

· Candidiasis of the mouth and throat (sometimes painful). Also tongue and throat irritated, and hoarse voice. Rinse your mouth with water and spit it out immediately after each shot can help prevent these effects. Your doctor may prescribe antifungal therapy to treat candidiasis.

· Tremors and fast or irregular heartbeat (palpitations). This is usually not serious and decreases with further treatment.

· Muscle cramps.

The following side effects have also been reported with Seretide in patients with Chronic Obstructive Pulmonary Disease (COPD):

· Pneumonia and bronchitis (respiratory infection). Tell your doctor if you experience any of the following: increased sputum, changes in sputum, fever, chills, increased cough, increased breathing difficulty.

· Bruising (blue on the skin) and fractures

· Inflammation of the sinuses (feeling of tension or heaviness in the face, cheeks and behind the eyes, sometimes accompanied by pulsating pain).

· Decrease in the amount of potassium in your blood (which can be manifested by palpitations, muscle weakness, cramps).

Infrequent effects (affect less than 1 in 100 people):

· Rashes of the urticaria type.

· Rapid acceleration of heart rate (tachycardia).

Very rare effects (affects less than 1 in 10,000 people):

· Sudden difficulty with breathing or wheezing immediately after inhaling the drug. In this case, stop using Seretide. Use your bronchodilator medication called ��rescue” to help you breathe and tell your doctor immediately.

· Seretide can affect the normal production of steroid hormones by the body (produced by the adrenal glands), especially if you have taken it at high doses and over long periods. The effects include:

o a slowdown in the growth of the child and the teenager,

o a thinning of the bone structure,

o a cataract (opacification of the lens of the eye generally causing visual discomfort), and glaucoma (an eye condition related to an increase in intraocular pressure),

o weight gain,

o a rounding (moon-shaped appearance) of the face (Cushing’s syndrome).

· Your doctor will regularly check that you do not have these side effects and that you are using Seretide at the lowest dose to control your asthma.

· Irregular heart rhythm (arrhythmias). Tell your doctor, but there is no need to stop your treatment unless your doctor tells you to stop.

· Increased sugar (glucose) in your blood (hyperglycemia). If you have diabetes, more frequent checks of your blood sugar level and a possible adjustment to your anti-diabetic treatment may be necessary. Feelings of worry, sleep disturbances and behavioral changes, such as unusual activity and irritability (these effects occur mainly in children).

· Pain and inflammation of the joints, muscle pain.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

seretide drug interactions

Beta-blockers, selective or not, should be avoided in patients with asthma unless absolutely necessary.

Concomitant administration of other beta-adrenergic agents may potentiate beta-2-mimetic effects.

Fluticasone propionate

Under normal conditions of use, fluticasone propionate plasma concentrations achieved after inhaled administration are low due to a significant presystemic first-pass effect (hepatic and intestinal) and high plasma clearance by extensive metabolism. mediated by cytochrome P450 3A4. As a result, the risk of clinically significant interactions with fluticasone propionate appears to be low.

Nevertheless, an interaction study in healthy volunteers receiving nasal fluticasone propionate showed that ritonavir (a very potent inhibitor of cytochrome P450 3A4) at a dose of 100 mg twice daily increased several hundred times plasma concentrations of fluticasone propionate, resulting in a marked decrease in plasma cortisol levels. There is no data documenting the interaction with fluticasone propionate administered by inhalation, but a significant increase in plasma concentrations is expected; cases of Cushing’s syndrome and inhibition of adrenal function have been reported. The concomitant administration of fluticasone propionate and ritonavir should therefore be avoided,

A low-dose study conducted in healthy volunteers showed that ketoconazole, a somewhat less potent inhibitor of cytochrome P450 3A4, increased the systemic exposure of a dose of inhaled fluticasone propionate by 150%. The reduction in plasma cortisol was greater than that observed after administration of fluticasone propionate alone. An increase in systemic exposure and the risk of systemic adverse reactions is expected when concomitant administration of other potent cytochrome P450 3A4 inhibitors (eg, itraconazole). Caution is advised and long-term combination therapy should be avoided as much as possible.

salmeterol

·Strong inhibitors of cytochrome P450 3A4

Concomitant administration of ketoconazole (400 mg orally once daily) and salmeterol (50 μg inhaled twice daily) in 15 healthy volunteers for 7 days resulted in a significant increase in plasma concentrations of salmeterol (Concentration maximum (Cmax) increased by a factor of 1.4 and area under the curve (AUC) increased by a factor of 15). This observation therefore suggests an increased risk of systemic effects of salmeterol, such as QT prolongation and palpitations, compared with salmeterol or ketoconazole alone (see Warnings and Precautions section). ).

There was no clinically significant effect on blood pressure, heart rate, blood glucose, and serum potassium. Concomitant administration of ketoconazole did not result in an extension of the half-life of salmeterol elimination or its accumulation after repeated dosing.

The combination of ketoconazole with salmeterol should be avoided unless the expected benefits outweigh the potential risk of systemic effects of salmeterol. A similar risk of interaction is expected with other potent cytochrome P450 3A4 inhibitors (eg with itraconazole, telithromycin, ritonavir).

· Moderate inhibitors of cytochrome P450 3A4

Concomitant administration of erythromycin (500 mg orally three times a day) and salmeterol (50 μg twice daily) in 15 healthy volunteers for 6 days resulted in a small but not statistically significant increase. plasma concentrations of salmeterol (Cmax increased by a factor of 1.4 and AUC increased by a factor of 1.2). No serious adverse events were associated with concomitant administration with erythromycin.

Seretide Warnings and Precautions

The adaptation of an anti-asthmatic treatment is done in stages according to the clinical state of the patient who will be regularly reassessed by a medical follow-up and the control of the respiratory function.

Seretide is not suitable for the treatment of asthma attacks and episodes of paroxysmal dyspnea. In these situations, the patient should use a short-acting, fast-acting bronchodilator to treat acute symptoms. The patient will be informed that he must therefore have at his disposal a fast-acting, short-acting bronchodilator for use in an asthma attack.

Treatment with Seretide should not be initiated during an exacerbation phase, or when there is a significant worsening or deterioration of asthma.

Serious asthma-related adverse events and exacerbations may occur during treatment with Seretide. Patients should be advised that if symptoms of asthma persist or worsen during treatment with Seretide, they should continue their treatment but seek advice from their doctor.

An increase in short-acting, fast-acting bronchodilator use to treat symptoms is a sign of destabilization of the disease. In this case, the patient will have to consult his doctor. A more or less rapid deterioration in symptom control should raise the risk of progression to severe acute asthma that may be life-threatening and therefore require urgent medical consultation. It will be advisable then to consider an increase of the corticotherapy. Similarly, if symptom control is still insufficient following treatment with Seretide, medical consultation is necessary and the prescription of additional corticosteroids should be considered.

As soon as the symptoms of asthma are controlled, a gradual decrease in the dose of Seretide should be considered. It is important that patients are followed regularly during the treatment reduction period. The minimum effective dose of Seretide should be used .

Seretide treatment should not be interrupted abruptly.

Like other corticosteroids for inhaled administration, Seretide should be used with caution in patients with pulmonary tuberculosis.

Rarely, Seretide can cause heart rhythm disorders such as supraventricular tachycardia, extrasystoles and atrial fibrillation, as well as a moderate and transient decrease in serum potassium at high therapeutic doses. Therefore, Seretide should be used with caution in cases of severe cardiovascular disease, cardiac arrhythmias, diabetes, hyperthyroidism, uncorrected hypokalaemia, or in patients at risk of hypokalemia.

Increases in blood glucose have been reported very rarely . This must be taken into account when prescribing to diabetic patients.

As with other inhaled products, increased bronchial whistling indicating bronchospasm following inhalation of the powder should lead to discontinuation of Seretide treatment and clinical examination of the patient. Treatment should be re-evaluated to consider alternative therapy as appropriate.

Caution should be taken when releasing Seretide for systemic corticosteroids, particularly in patients who may have impaired adrenal function.

Inhaled corticosteroid therapy may have systemic effects, especially during long-term high-dose therapy. The occurrence of these effects remains less likely than during oral corticosteroid therapy. Cushing’s syndrome, a cushingoid picture, an inhibition of adrenal function, a decrease in bone mineral density, a cataract and glaucoma can be observed. As a result, the patient will be followed regularly and the minimum effective dosage should always be sought.

Prolonged administration of high doses of inhaled corticosteroids may result in inhibition of adrenal function by promoting the occurrence of acute adrenal insufficiency. Cases of inhibition of adrenal function and acute adrenal insufficiency have also been very rarely described with fluticasone propionate doses of between 500 and 1000 micrograms. Adrenal insufficiency attacks can be triggered by trauma, surgery, infection or any rapid decrease in dosage. The clinical picture is usually atypical and may include anorexia, abdominal pain, weight loss, fatigue, headache, nausea, vomiting, hypotension, disturbance of consciousness, hypoglycemia and convulsions.

Fluticasone propionate and salmeterol are mainly absorbed by the pulmonary route. The use of an inhalation chamber associated with the metered dose inhaler may increase the dose of product delivered to the lung, thereby increasing the risk of systemic adverse reactions. Single-dose kinetic data showed twice as much systemic exposure when Seretide was administered using the AeroChamber Plus inhalation chamber compared to the Volumatic inhalation chamber.

The use of inhaled fluticasone propionate reduces the need for oral corticosteroids to treat asthma, but it does not prevent the risk of developing adrenal insufficiency when patients treated with long-term oral corticotherapy. This risk also exists in patients who have received high doses of emergency corticosteroids. The risk of persistence of adrenal suppression should be kept in mind in emergency situations and / or likely to trigger a state of stress. Appropriate corticosteroid replacement therapy should be considered. A specialized opinion may be required.

Ritonavir can dramatically increase plasma concentrations of fluticasone propionate. Therefore, unless the expected benefit to the patient outweighs the risk of systemic effects of corticosteroid therapy, concomitant administration should be avoided. The risk of systemic effects of corticosteroid therapy is also increased when concomitant administration of fluticasone propionate with other potent cytochrome P450 3A4 inhibitors .

An increase in cases of low respiratory infections (especially pneumonia and bronchitis) was observed in a 3-year study (TORCH study) in patients with COPD treated with Seretide, compared to those receiving placebo . In this study, the risk of developing pneumonia, regardless of treatment, was highest in elderly patients, patients with low body mass index (<25 kg / m2) and those with very severe disease (FEV 1 < 30% of the theoretical value). The possibility of pneumonia or other low respiratory infections in patients with chronic obstructive pulmonary disease (COPD) should be carefully monitored as the clinical manifestations of infection are often confused with a simple exacerbation. The occurrence of pneumonia in a patient with severe COPD should lead to re-evaluation of Seretide therapy.

Data from a large-scale clinical trial (“Salmeterol Multi-Center Asthma Research Trial, SMART”) suggested an increased risk of serious respiratory adverse events or respiratory-related death in African patients. treated with salmeterol compared to placebo . It could not be determined whether these observations were of pharmacogenetic origin or resulted from other intercurrent factors. If symptoms of asthma persist or worsen during treatment with Seretide, patients of African-African or Afro-Caribbean origin should continue Seretide treatment while promptly seeking medical attention.

Co-administration of systemic ketoconazole significantly increases systemic exposure to salmeterol, which may increase the risk of systemic effects (eg prolongation of QTc interval and palpitations). Therefore, concomitant administration of ketoconazole or other potent inhibitors of cytochrome P450 3A4 should be avoided unless the expected benefits outweigh the potential risk of systemic effects of salmeterol .

Athletes’ attention will be drawn to the fact that this specialty contains two active ingredients that can induce a positive reaction of the tests performed during doping controls.

Pediatric population

Children and adolescents under 16 years of age receiving high doses of fluticasone propionate (usually ≥ 1000 micrograms daily) are at particular risk. Systemic effects may occur, especially during long-term high-dose treatments. Cushing’s syndrome, a cushingoid picture, an inhibition of adrenal function, acute adrenal insufficiency and stunting in children and adolescents can be observed.

The growth of children receiving long-term inhaled corticosteroid therapy should be monitored regularly. Inhaled corticosteroid therapy should be reduced to the lowest dose for effective asthma control.

Drive and use machines

There are no studies evaluating the effects of this drug on the ability to drive and use machines.

Seretide and PREGNANCY / BREAST FEEDING / FERTILITY:

seretide and fertility

There is no data in humans. However, animal studies have shown no effect of salmeterol or fluticasone propionate on fertility.

seretide during pregnancy

A moderate amount of data obtained in pregnant women (between 300 and 1000 cases of documented pregnancies) do not report the malformative or fetononatal toxicity of salmeterol and fluticasone propionate. Studies in animals on reproductive functions have shown a toxicity of ß-2-mimetics and glucocorticoids ( see Preclinical safety ).Use of Seretide during pregnancy should only be considered if the expected benefit to the mother outweighs any potential risk to the fetus.

In pregnant women, the minimum effective dose of fluticasone propionate should be sought for satisfactory control of the symptoms of asthma.

Breastfeeding

The passage of salmeterol and fluticasone propionate and their metabolites into breast milk is not known.Studies have shown that salmeterol and fluticasone propionate, and their metabolites, are excreted in the milk of lactating rats.

A risk for breastfed newborns / infants can not be ruled out. The decision to discontinue breastfeeding or treatment with Seretide will be based on the expected benefit of breastfeeding for the child compared to the treatment for the breastfeeding woman.

What should I do if I miss a dose?

If you forget to take your medicine

take the next dose at the usual time.

Do not take a double dose to make up for the single dose you forgot to take.

What happens if I overdose from Seretide ?

It is important to use the device as your doctor has shown you. If you accidentally take more than the recommended dose, tell your doctor or pharmacist. You may notice an increased heart rate and tremors. You may also experience headaches, muscle weakness and joint pain.

If you have taken large doses for a long time, talk to your doctor or pharmacist. High doses administered in the long term may result in a decrease in the steroid hormones secreted by the adrenal glands.

What is Forms and Composition Seretide?

FORMS and PRESENTATIONS

Seretide: Inhalation suspension at 50 μg / 25 μg / dose, at 125 μg / 25 μg / dose and at 250 μg / 25 μg / dose (white to whitish): Pressurized 8 ml (120 doses) vial with metering valve. The cartridge is inserted in a purple plastic applicator with a mouthpiece closed by a cap, with a dose counter to indicate the number of doses remaining.

Seretide Diskus: Inhalation powder at 100 μg / 50 μg / dose, 250 μg / 50 μg / dose and 500 μg / 50 μg / dose: Distributor (Diskus) of 60 single-dose containers (regularly spaced), under heat-sealed film. Hospital models: Distributor (Diskus) of 28 single-dose containers, under heat-sealed film.

COMPOSITION

Seretide:

p dose *p dose deliveredFluticasone (DCI) propionate50 μg44 μgor125 μg110 μgor250 μg220 μgSalmeterol (INN) xinafoate expressed as salmeterol25 μg21 μg

* Issued by the metering valve. Excipient (common): norflurane (HFA 134a, propellant).

Seretide Diskus:

p dose *p dose delivered **Fluticasone (DCI) propionate100 μg92 μgor250 μg231 μgor500 μg460 μgSalmeterol (INN) xinafoate expressed as salmeterol50 μg47 μg

* Contained in each single-dose container.

** At the mouthpiece. Excipient (common): lactose monohydrate (containing milk proteins).

Lactose content: up to 12.5 mg / dose.

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

General explanation about dealing with the medicine: how to take the medicine, the doses and times of it, the start and duration of its effectiveness, the recommended diet during the period of taking the medicine, the method of storage and storage, recommendations in cases for forgetting the dose and instructions to stop taking the drug and take additional doses.

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post Seretide drug Uses, Dosage, Side Effects, Precautions & Warnings appeared first on Drug Online.

from Drug Online https://bit.ly/3gxRDrV via Edrug Online from Faculty of Medicine https://bit.ly/3iXQfiD via Internal Medicine

#medicines #including Allergy Medicines #Anemia #Antibiotic Medicines #Colds & Flu Medicines #Cough Me

0 notes

thesittingduck · 4 years ago

Text

Seretide drug Uses, Dosage, Side Effects, Precautions & Warnings

Drug Online

seretide drug class >>Generic drug of the therapeutic class: Pulmonology active ingredients: Fluticasone , Salmeterol

Important to know about Seretide ?

Asthma.

You must use Seretide every day as directed by your doctor. This will properly control your asthma.

What is Seretide used for and indication ?

What is Seretide used for

Seretide and Seretide Diskus:

Asthma:

Continuous treatment of asthma, in situations where the inhaled administration of a combination corticosteroid and long-acting ß-2 agonist bronchodilator is warranted:

in patients inadequately controlled by inhaled corticosteroid therapy and a short-acting ß-2 agonist bronchodilator by inhalation “on demand”, or

in patients controlled by the administration of inhaled corticosteroids associated with continuous therapy with inhaled long-acting ß-2 agonist.

Note :

Seretide Inhalation Suspension 50 μg / 25 μg / dose and Seretide Diskus 100 μg / 50 μg / dose are not suitable for the treatment of severe adult and pediatric asthma.

Seretide Diskus at 500 μg / 50 μg / dose:

Chronic Obstructive Pulmonary Disease (COPD):

seretide dosage 250/50/25

Inhaled route only.

The patient should be informed that to observe an optimal treatment effect, Seretide should be administered daily even when symptoms are improved.

The doctor should regularly check that the prescribed dosage of Seretide is well adapted to the clinical condition of the patient. It will only be changed with medical advice.

The minimum effective dosage should always be sought. When symptoms are controlled by the lowest recommended dose twice daily, then inhaled corticosteroid alone will be considered.

It may also be considered to reduce the dosage of Seretide once a day, if the physician considers it necessary to maintain a long-acting beta-2 mimetic treatment for symptom control.

The time of taking Seretide will then depend on the frequency of appearance of symptoms. If the predominance of symptoms is nocturnal, Seretide will be given in the evening; if it is diurnal,

Recommended dosage:

Asthma

seretide dosage Adults and Teens 12 years and older:

Two inhalations of 50 μg of fluticasone propionate and 25 μg of salmeterol twice daily..or

Two inhalations of 125 μg fluticasone propionate and 25 μg salmeterol 2 times daily..or

Two inhalations of 250 μg of fluticasone propionate and 25 μg of salmeterol twice daily..or

Children 4 years old and over:

Two inhalations of 50 μg of fluticasone propionate and 25 μg of salmeterol twice daily.

In children, the recommended maximum dose of inhaled fluticasone propionate is 100 micrograms twice daily.

No data are available on the use of Seretide in children under 4 years of age.

Populations at risk:

There is no need to adjust doses in elderly or renally impaired patients. No data are available on the use of Seretide in patients with hepatic impairment.

Contraindications

Salmeterol hypersensitivity

Fluticasone hypersensitivity

Norflurane hypersensitivity

Feeding with milk

Pregnancy

Hypersensitivity to the active substances or to any of the excipients listed in the Composition section.

seretide how to use

Patients should be informed about how the metered dose inhaler works (see leaflet).

During inhalation, the patient should preferably sit or stand. The aerosol has been designed for use in a vertical position.

Verification of the operation of the device:

Use of the aerosol:

The patient should remove the cap from the mouthpiece by exerting pressure on each side.

The patient should check that there is no foreign body inside or outside the device, including the mouthpiece, to ensure that it is clean.

The patient should shake the aerosol well to remove any foreign matter and ensure mixing of the suspension components in the vial.

The patient should hold the aerosol straight between the fingers and thumb with his thumb at the base, under the mouthpiece.

The patient should exhale as much as possible then place the mouthpiece in his mouth between the teeth and close the lips around. Tell the patient that they should not bite the mouthpiece.

While holding his breath, the patient will remove the inhaler from his mouth. The patient will hold his breath as much as possible.

If the patient is to take a second inhalation, he / she should keep the MDI straight and wait about 30 seconds before repeating steps 3 to 7.

IMPORTANT

Patients should never try to change the numbers on the meter or detach it from the metal cartridge. The counter can not be reset and remains permanently attached to the cartridge.

Cleaning :

The device should be cleaned at least once a week.

Remove the cap from the mouthpiece.

Do not remove the cartridge from its plastic adapter.

Wipe the inside and outside of the mouthpiece and plastic adapter with a clean, dry tissue or tissue.

DO NOT PUT THE METAL CARTRIDGE IN WATER.

how does seretide works

Pharmacotherapeutic group: Adrenergic and other drugs for obstructive airways syndromes

ATC Code: R03AK06

Clinical studies conducted with the propionate combination of fluticasone / salmeterol in asthma:

The overall results of the study were as follows:

Percentage of patients achieving * Good Control (BC) and ** Total Control (CT) of asthma over 12 months

Treatment before inclusion in the study

FP 4 / Salmeterol

FP 4

No CSI 1 (ß2 CDA 2 alone)

78%

50%

70%

40%

Low dose ICS (≤ 500 μg BDP 3 or equivalent per day)

75%

44%

60%

28%

Medium dose ICS (> 500-1000 μg BDP 3 or equivalent per day)

62%

29%

47%

16%

Overall results (regardless of previous treatment)

71%

41%

59%

28%

CSI: inhaled corticosteroids

ß2 CDA: Beta-2 short-acting agonist

BDP: beclometasone dipropionate

FP: Fluticasone Propionate

Multicenter trial in asthma with salmeterol (“Salmeterol Multi-Center Asthma Research Trial, SMART”)

Results of the SMART study on the primary endpoint:

Patient groups

Main criterion:

Number of events /

number of patients

Relative risk

(95% Confidence Interval)

salmeterol

placebo

Overall population included

50/13176

36/13179

1.40 (0.91, 2.14)

Patients using inhaled corticosteroids

23/6127

19/6138

1.21 (0.66, 2.23)

Patients not using inhaled corticosteroids

27/7049

17/7041

1.60 (0.87, 2.93)

Subgroup of African-American patients

20/2366

5/2319

4.10 (1.54, 10.90) **

** statistically significant at 95%

Other results of the SMART study according to whether or not inhaled corticosteroids were taken at baseline:

Secondary criteria:

Number of events / number of patients

Relative risk

(95% Confidence Interval)

salmeterol

placebo

Number of deaths related to a respiratory cause

Patients using inhaled corticosteroids

10/6127

5/6138

2.01 (0.69, 5.86)

Patients not using inhaled corticosteroids

14/7049

6/7041

2.28 (0.88, 5.94)

Combined criterion combining asthma episodes that have led to death or life-threatening

Patients using inhaled corticosteroids

16/6127

13/6138

1.24 (0.60; 2.58)

Patients not using inhaled corticosteroids

21/7049

9/7041

2.39 (1.10, 5.22) **

Number of deaths related to asthma

Patients using inhaled corticosteroids

4/6127

3/6138

1.35 (0.30, 6.04)

Patients not using inhaled corticosteroids

9/7049

0/7041

* = relative risk could not be calculated due to no event in the placebo group.

** The results are statistically significant at 95%. The secondary criteria in the table above reached statistical significance in the entire study population.

Action mechanism

Seretide contains salmeterol and fluticasone propionate which have different modes of action:

salmeterol

Salmeterol is a selective long-acting agonist (12 hours) for beta-2 adrenergic receptors. It has a long side chain that links it to the receiver’s exo-site.

Salmeterol produces bronchodilation which persists for about 12 hours. This duration is greater than that generally observed with short-acting beta-2 mimetics administered at the usual dosages.

Fluticasone propionate

Does Seretide have side effects?

yes it’s and this’s Description of adverse effects

Like all medicines, SERETIDE 50 micrograms / 25 micrograms / dose, suspension for inhalation in a pressurized bottle can cause side effects, but they do not occur systematically in everyone.

To prevent the occurrence of side effects, your doctor will prescribe the lowest possible dose to control your asthma.

Other side effects are described below:

Very common effects (affects more than 1 in 10 people):

· Headache usually decreases with further treatment.

· An increase in colds has been reported in patients with Chronic Obstructive Pulmonary Disease (COPD) treated with Seretide.

Common effects (affect less than 1 in 10 people):

· Tremors and fast or irregular heartbeat (palpitations). This is usually not serious and decreases with further treatment.

· Muscle cramps.

The following side effects have also been reported with Seretide in patients with Chronic Obstructive Pulmonary Disease (COPD):

· Bruising (blue on the skin) and fractures

· Inflammation of the sinuses (feeling of tension or heaviness in the face, cheeks and behind the eyes, sometimes accompanied by pulsating pain).

· Decrease in the amount of potassium in your blood (which can be manifested by palpitations, muscle weakness, cramps).

Infrequent effects (affect less than 1 in 100 people):

· Rashes of the urticaria type.

· Rapid acceleration of heart rate (tachycardia).

Very rare effects (affects less than 1 in 10,000 people):

· Sudden difficulty with breathing or wheezing immediately after inhaling the drug. In this case, stop using Seretide. Use your bronchodilator medication called “rescue” to help you breathe and tell your doctor immediately.

o a slowdown in the growth of the child and the teenager,

o a thinning of the bone structure,

o a cataract (opacification of the lens of the eye generally causing visual discomfort), and glaucoma (an eye condition related to an increase in intraocular pressure),

o weight gain,

o a rounding (moon-shaped appearance) of the face (Cushing’s syndrome).

· Your doctor will regularly check that you do not have these side effects and that you are using Seretide at the lowest dose to control your asthma.

· Irregular heart rhythm (arrhythmias). Tell your doctor, but there is no need to stop your treatment unless your doctor tells you to stop.

· Pain and inflammation of the joints, muscle pain.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

seretide drug interactions

Beta-blockers, selective or not, should be avoided in patients with asthma unless absolutely necessary.

Concomitant administration of other beta-adrenergic agents may potentiate beta-2-mimetic effects.

Fluticasone propionate

salmeterol

·Strong inhibitors of cytochrome P450 3A4

· Moderate inhibitors of cytochrome P450 3A4

Seretide Warnings and Precautions

Treatment with Seretide should not be initiated during an exacerbation phase, or when there is a significant worsening or deterioration of asthma.

Seretide treatment should not be interrupted abruptly.

Like other corticosteroids for inhaled administration, Seretide should be used with caution in patients with pulmonary tuberculosis.

Increases in blood glucose have been reported very rarely . This must be taken into account when prescribing to diabetic patients.

Caution should be taken when releasing Seretide for systemic corticosteroids, particularly in patients who may have impaired adrenal function.

Athletes’ attention will be drawn to the fact that this specialty contains two active ingredients that can induce a positive reaction of the tests performed during doping controls.

Pediatric population

Drive and use machines

There are no studies evaluating the effects of this drug on the ability to drive and use machines.

Seretide and PREGNANCY / BREAST FEEDING / FERTILITY:

seretide and fertility

There is no data in humans. However, animal studies have shown no effect of salmeterol or fluticasone propionate on fertility.

seretide during pregnancy

In pregnant women, the minimum effective dose of fluticasone propionate should be sought for satisfactory control of the symptoms of asthma.

Breastfeeding

What should I do if I miss a dose?

If you forget to take your medicine

take the next dose at the usual time.

Do not take a double dose to make up for the single dose you forgot to take.

What happens if I overdose from Seretide ?

What is Forms and Composition Seretide?

FORMS and PRESENTATIONS

COMPOSITION

Seretide:

p dose * p dose delivered Fluticasone (DCI) propionate 50 μg 44 μg or 125 μg 110 μg or 250 μg 220 μg Salmeterol (INN) xinafoate expressed as salmeterol 25 μg 21 μg

* Issued by the metering valve. Excipient (common): norflurane (HFA 134a, propellant).

Seretide Diskus:

p dose * p dose delivered ** Fluticasone (DCI) propionate 100 μg 92 μg or 250 μg 231 μg or 500 μg 460 μg Salmeterol (INN) xinafoate expressed as salmeterol 50 μg 47 μg

* Contained in each single-dose container.

** At the mouthpiece. Excipient (common): lactose monohydrate (containing milk proteins).

Lactose content: up to 12.5 mg / dose.

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post Seretide drug Uses, Dosage, Side Effects, Precautions & Warnings appeared first on Drug Online.

from Drug Online https://bit.ly/3gxRDrV via Edrug Online from faculty of medicine https://bit.ly/3aGAIkt via Faculty of Medicine

#medicines #including Allergy Medicines #Anemia #Antibiotic Medicines #Colds & Flu Medicines #Cough Me

0 notes

sffgtrhyjhmnzdt · 11 months ago

Text

Advances in Pulmonology Treatment: A Comprehensive Overview

Pulmonology, a branch of medicine focused on the respiratory system, has witnessed remarkable advancements in recent years. From innovative therapies to cutting-edge diagnostic tools, the field has evolved to provide more effective and personalized treatment options for patients with respiratory conditions. In this Bhanu Heart Care, we will explore some of the latest developments in pulmonology treatment in miyapur, offering insights into groundbreaking approaches that are shaping the future of respiratory care.

Precision Medicine in Pulmonary Care:

Recent strides in genomic research have paved the way for precision medicine in pulmonology. Genetic profiling allows healthcare professionals, including pulmonary surgeon in chandanagar, to identify specific mutations or biomarkers associated with respiratory diseases, enabling tailored treatment plans. This approach holds promise for conditions like cystic fibrosis, where targeted therapies can address the underlying genetic abnormalities.

Immunotherapy for Respiratory Disorders:

Immunotherapy, once predominantly associated with oncology, is emerging as a game-changer in pulmonology. By modulating the immune system, these therapies show potential in treating conditions such as asthma and chronic obstructive pulmonary disease (COPD). Pulmonology clinics may offer these innovative treatments, including immune checkpoint inhibitors and monoclonal antibodies for managing inflammatory lung diseases.

Advancements in Inhalation Therapy:

Inhalation therapy remains a cornerstone in treating respiratory conditions, and recent developments have enhanced its effectiveness. Pulmonary specialists may prescribe novel inhaled medications, including long-acting bronchodilators and anti-inflammatory agents, to improve symptom control and quality of life for patients. Pulmonology services in miyapur may also include the use of smart inhalers with sensors for real-time monitoring.

Telemedicine in Respiratory Care:

The widespread adoption of telemedicine has transformed the delivery of healthcare services, including pulmonology. Pulmonology hospital in madinaguda are incorporating remote monitoring devices and teleconsultations, enabling healthcare providers to assess patients' lung function, track symptoms, and adjust treatment plans without the need for frequent in-person visits. This approach not only improves patient convenience but also facilitates timely intervention and management.

Lung Transplantation Innovations:

Lung transplantation, a critical intervention often performed by pulmonology surgeons, remains a viable option for individuals with end-stage lung diseases. Advances in organ preservation techniques, donor selection criteria, and post-transplant care have significantly improved transplant outcomes. Pulmonology hospitals play a crucial role in the evaluation, preparation, and ongoing care of patients undergoing lung transplantation.

As pulmonology services continue to evolve, these advancements underscore the commitment of healthcare professionals, including pulmonary specialist doctor in madinaguda and pulmonology surgeons, to enhance the lives of individuals affected by respiratory conditions. From precision medicine to innovative inhalation therapies and the integration of telemedicine, the landscape of pulmonology treatment is becoming increasingly sophisticated. These developments not only offer hope to patients but also contribute to the ongoing efforts of pulmonology clinics and hospitals to better understand, manage, and ultimately conquer respiratory diseases.

#pulmonology surgeon in chandanagar #pulmonary specialist doctor in madinaguda #pulmonology surgeon in madinaguda #pulmonology services in madinaguda #pulmonology surgeon in miyapur #pulmonology services in miyapur #pulmonology treatment in miyapur #pulmonary specialist doctor in miyapur #pulmonology clinic in madinaguda #pulmonology hospital in madinaguda

0 notes

colinfitzpatrick · 4 years ago

Text

Seretide drug Uses, Dosage, Side Effects, Precautions & Warnings

Drug Online

seretide drug class >>Generic drug of the therapeutic class: Pulmonology active ingredients: Fluticasone , Salmeterol

Important to know about Seretide ?

Asthma.

You must use Seretide every day as directed by your doctor. This will properly control your asthma.

What is Seretide used for and indication ?

What is Seretide used for

Seretide and Seretide Diskus:

Asthma:

Continuous treatment of asthma, in situations where the inhaled administration of a combination corticosteroid and long-acting ß-2 agonist bronchodilator is warranted:

in patients inadequately controlled by inhaled corticosteroid therapy and a short-acting ß-2 agonist bronchodilator by inhalation “on demand”, or

in patients controlled by the administration of inhaled corticosteroids associated with continuous therapy with inhaled long-acting ß-2 agonist.

Note :

Seretide Inhalation Suspension 50 μg / 25 μg / dose and Seretide Diskus 100 μg / 50 μg / dose are not suitable for the treatment of severe adult and pediatric asthma.

Seretide Diskus at 500 μg / 50 μg / dose:

Chronic Obstructive Pulmonary Disease (COPD):

seretide dosage 250/50/25

Inhaled route only.

The patient should be informed that to observe an optimal treatment effect, Seretide should be administered daily even when symptoms are improved.

The doctor should regularly check that the prescribed dosage of Seretide is well adapted to the clinical condition of the patient. It will only be changed with medical advice.

The minimum effective dosage should always be sought. When symptoms are controlled by the lowest recommended dose twice daily, then inhaled corticosteroid alone will be considered.

It may also be considered to reduce the dosage of Seretide once a day, if the physician considers it necessary to maintain a long-acting beta-2 mimetic treatment for symptom control.

The time of taking Seretide will then depend on the frequency of appearance of symptoms. If the predominance of symptoms is nocturnal, Seretide will be given in the evening; if it is diurnal,

Recommended dosage:

Asthma

seretide dosage Adults and Teens 12 years and older:

Two inhalations of 50 μg of fluticasone propionate and 25 μg of salmeterol twice daily..or

Two inhalations of 125 μg fluticasone propionate and 25 μg salmeterol 2 times daily..or

Two inhalations of 250 μg of fluticasone propionate and 25 μg of salmeterol twice daily..or

Children 4 years old and over:

Two inhalations of 50 μg of fluticasone propionate and 25 μg of salmeterol twice daily.

In children, the recommended maximum dose of inhaled fluticasone propionate is 100 micrograms twice daily.

No data are available on the use of Seretide in children under 4 years of age.

Populations at risk:

There is no need to adjust doses in elderly or renally impaired patients. No data are available on the use of Seretide in patients with hepatic impairment.

Contraindications

Salmeterol hypersensitivity

Fluticasone hypersensitivity

Norflurane hypersensitivity

Feeding with milk

Pregnancy

Hypersensitivity to the active substances or to any of the excipients listed in the Composition section.

seretide how to use

Patients should be informed about how the metered dose inhaler works (see leaflet).

During inhalation, the patient should preferably sit or stand. The aerosol has been designed for use in a vertical position.

Verification of the operation of the device:

Use of the aerosol:

The patient should remove the cap from the mouthpiece by exerting pressure on each side.

The patient should check that there is no foreign body inside or outside the device, including the mouthpiece, to ensure that it is clean.

The patient should shake the aerosol well to remove any foreign matter and ensure mixing of the suspension components in the vial.

The patient should hold the aerosol straight between the fingers and thumb with his thumb at the base, under the mouthpiece.

The patient should exhale as much as possible then place the mouthpiece in his mouth between the teeth and close the lips around. Tell the patient that they should not bite the mouthpiece.

While holding his breath, the patient will remove the inhaler from his mouth. The patient will hold his breath as much as possible.

If the patient is to take a second inhalation, he / she should keep the MDI straight and wait about 30 seconds before repeating steps 3 to 7.

IMPORTANT

Patients should never try to change the numbers on the meter or detach it from the metal cartridge. The counter can not be reset and remains permanently attached to the cartridge.

Cleaning :

The device should be cleaned at least once a week.

Remove the cap from the mouthpiece.

Do not remove the cartridge from its plastic adapter.

Wipe the inside and outside of the mouthpiece and plastic adapter with a clean, dry tissue or tissue.

DO NOT PUT THE METAL CARTRIDGE IN WATER.

how does seretide works

Pharmacotherapeutic group: Adrenergic and other drugs for obstructive airways syndromes

ATC Code: R03AK06

Clinical studies conducted with the propionate combination of fluticasone / salmeterol in asthma:

The overall results of the study were as follows:

Percentage of patients achieving * Good Control (BC) and ** Total Control (CT) of asthma over 12 months

Treatment before inclusion in the study

FP 4 / Salmeterol

FP 4

No CSI 1 (ß2 CDA 2 alone)

78%

50%

70%

40%

Low dose ICS (≤ 500 μg BDP 3 or equivalent per day)

75%

44%

60%

28%

Medium dose ICS (> 500-1000 μg BDP 3 or equivalent per day)

62%

29%

47%

16%

Overall results (regardless of previous treatment)

71%

41%

59%

28%

CSI: inhaled corticosteroids

ß2 CDA: Beta-2 short-acting agonist

BDP: beclometasone dipropionate

FP: Fluticasone Propionate

Multicenter trial in asthma with salmeterol (“Salmeterol Multi-Center Asthma Research Trial, SMART”)

Results of the SMART study on the primary endpoint:

Patient groups

Main criterion:

Number of events /

number of patients

Relative risk

(95% Confidence Interval)

salmeterol

placebo

Overall population included

50/13176

36/13179

1.40 (0.91, 2.14)

Patients using inhaled corticosteroids

23/6127

19/6138

1.21 (0.66, 2.23)

Patients not using inhaled corticosteroids

27/7049

17/7041

1.60 (0.87, 2.93)

Subgroup of African-American patients

20/2366

5/2319

4.10 (1.54, 10.90) **

** statistically significant at 95%

Other results of the SMART study according to whether or not inhaled corticosteroids were taken at baseline:

Secondary criteria:

Number of events / number of patients

Relative risk

(95% Confidence Interval)

salmeterol

placebo

Number of deaths related to a respiratory cause

Patients using inhaled corticosteroids

10/6127

5/6138

2.01 (0.69, 5.86)

Patients not using inhaled corticosteroids

14/7049

6/7041

2.28 (0.88, 5.94)

Combined criterion combining asthma episodes that have led to death or life-threatening

Patients using inhaled corticosteroids

16/6127

13/6138

1.24 (0.60; 2.58)

Patients not using inhaled corticosteroids

21/7049

9/7041

2.39 (1.10, 5.22) **

Number of deaths related to asthma

Patients using inhaled corticosteroids

4/6127

3/6138

1.35 (0.30, 6.04)

Patients not using inhaled corticosteroids

9/7049

0/7041

* = relative risk could not be calculated due to no event in the placebo group.

** The results are statistically significant at 95%. The secondary criteria in the table above reached statistical significance in the entire study population.

Action mechanism

Seretide contains salmeterol and fluticasone propionate which have different modes of action:

salmeterol

Salmeterol is a selective long-acting agonist (12 hours) for beta-2 adrenergic receptors. It has a long side chain that links it to the receiver’s exo-site.

Salmeterol produces bronchodilation which persists for about 12 hours. This duration is greater than that generally observed with short-acting beta-2 mimetics administered at the usual dosages.

Fluticasone propionate

Does Seretide have side effects?

yes it’s and this’s Description of adverse effects

Like all medicines, SERETIDE 50 micrograms / 25 micrograms / dose, suspension for inhalation in a pressurized bottle can cause side effects, but they do not occur systematically in everyone.

To prevent the occurrence of side effects, your doctor will prescribe the lowest possible dose to control your asthma.

Other side effects are described below:

Very common effects (affects more than 1 in 10 people):

· Headache usually decreases with further treatment.

· An increase in colds has been reported in patients with Chronic Obstructive Pulmonary Disease (COPD) treated with Seretide.

Common effects (affect less than 1 in 10 people):

· Tremors and fast or irregular heartbeat (palpitations). This is usually not serious and decreases with further treatment.

· Muscle cramps.

The following side effects have also been reported with Seretide in patients with Chronic Obstructive Pulmonary Disease (COPD):

· Bruising (blue on the skin) and fractures

· Inflammation of the sinuses (feeling of tension or heaviness in the face, cheeks and behind the eyes, sometimes accompanied by pulsating pain).

· Decrease in the amount of potassium in your blood (which can be manifested by palpitations, muscle weakness, cramps).

Infrequent effects (affect less than 1 in 100 people):

· Rashes of the urticaria type.

· Rapid acceleration of heart rate (tachycardia).

Very rare effects (affects less than 1 in 10,000 people):

o a slowdown in the growth of the child and the teenager,

o a thinning of the bone structure,

o a cataract (opacification of the lens of the eye generally causing visual discomfort), and glaucoma (an eye condition related to an increase in intraocular pressure),

o weight gain,

o a rounding (moon-shaped appearance) of the face (Cushing’s syndrome).

· Your doctor will regularly check that you do not have these side effects and that you are using Seretide at the lowest dose to control your asthma.

· Irregular heart rhythm (arrhythmias). Tell your doctor, but there is no need to stop your treatment unless your doctor tells you to stop.

· Pain and inflammation of the joints, muscle pain.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

seretide drug interactions

Beta-blockers, selective or not, should be avoided in patients with asthma unless absolutely necessary.

Concomitant administration of other beta-adrenergic agents may potentiate beta-2-mimetic effects.

Fluticasone propionate

salmeterol

·Strong inhibitors of cytochrome P450 3A4

· Moderate inhibitors of cytochrome P450 3A4

Seretide Warnings and Precautions

Treatment with Seretide should not be initiated during an exacerbation phase, or when there is a significant worsening or deterioration of asthma.

Seretide treatment should not be interrupted abruptly.

Like other corticosteroids for inhaled administration, Seretide should be used with caution in patients with pulmonary tuberculosis.

Increases in blood glucose have been reported very rarely . This must be taken into account when prescribing to diabetic patients.

Caution should be taken when releasing Seretide for systemic corticosteroids, particularly in patients who may have impaired adrenal function.

Athletes’ attention will be drawn to the fact that this specialty contains two active ingredients that can induce a positive reaction of the tests performed during doping controls.

Pediatric population

Drive and use machines

There are no studies evaluating the effects of this drug on the ability to drive and use machines.

Seretide and PREGNANCY / BREAST FEEDING / FERTILITY:

seretide and fertility

There is no data in humans. However, animal studies have shown no effect of salmeterol or fluticasone propionate on fertility.

seretide during pregnancy

In pregnant women, the minimum effective dose of fluticasone propionate should be sought for satisfactory control of the symptoms of asthma.

Breastfeeding

What should I do if I miss a dose?

If you forget to take your medicine

take the next dose at the usual time.

Do not take a double dose to make up for the single dose you forgot to take.

What happens if I overdose from Seretide ?

What is Forms and Composition Seretide?

FORMS and PRESENTATIONS

COMPOSITION

Seretide:

p dose * p dose delivered Fluticasone (DCI) propionate 50 μg 44 μg or 125 μg 110 μg or 250 μg 220 μg Salmeterol (INN) xinafoate expressed as salmeterol 25 μg 21 μg

* Issued by the metering valve. Excipient (common): norflurane (HFA 134a, propellant).

Seretide Diskus:

p dose * p dose delivered ** Fluticasone (DCI) propionate 100 μg 92 μg or 250 μg 231 μg or 500 μg 460 μg Salmeterol (INN) xinafoate expressed as salmeterol 50 μg 47 μg

* Contained in each single-dose container.

** At the mouthpiece. Excipient (common): lactose monohydrate (containing milk proteins).

Lactose content: up to 12.5 mg / dose.

NOT’s

Edrug-online contains comprehensive and detailed information about drugs available in the medical field, and is divided into four sections:

general information:

Includes a general description of the drug, its use, brand names, FAQs, and relevant news and articles

Additional information:

Special warnings:

For pregnant and breastfeeding women, the elderly, boys and drivers, and use before surgery.

Side effects:

It treats possible side effects and drug interactions that require attention and its effect on continuous use.

The information contained in this medicine is based on medical literature, but it is not a substitute for consulting a doctor.

The post Seretide drug Uses, Dosage, Side Effects, Precautions & Warnings appeared first on Drug Online.

from Drug Online https://bit.ly/3gxRDrV via Edrug Online

#medicines #including Allergy Medicines #Anemia #Antibiotic Medicines #Colds & Flu Medicines #Cough Me

0 notes

gordonwilliamsweb · 5 years ago

Text

Not So Fast Using CPAPs In Place Of Ventilators. They Could Spread The Coronavirus.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases. In Italy, where hospitals have been overwhelmed with patients in respiratory failure, doctors have had to make difficult life-or-death decisions about who gets a ventilator and who does not.

In the U.S., emergency plans developed by states for a shortage of ventilators include using positive airway pressure machines — like those used to treat sleep apnea — to help hospitalized people with less severe breathing issues.

While that measure could stretch the supply of ventilators and save lives, it has a major drawback. Officials and scientists have known for years that when used with a face mask such alternative devices can possibly increase the spread of infectious disease by aerosolizing the virus, whether used in the hospital or at home.

Indeed, that very scenario may have contributed to the spread of COVID-19 within a Washington state nursing home that became ground zero in the United States early on. First responders called to the Life Care Center of Kirkland starting Feb. 24 initially used continuous positive airway pressure machines, often known as CPAPs, to treat residents before it was known the patients were infected with the COVID-19 virus.

“It’s best practice for us for people with respiratory illnesses,” said Jim Whitney, medical services administrator for the Redmond Fire Department, whose crews responded to the nursing home’s 911 calls. “We had no idea that we potentially had COVID patients there.”

Email Sign-Up

Subscribe to KHN’s free Morning Briefing.

Please confirm your email address below:

It was only later that King County public health officials advised Redmond Fire and other first responders in the region not to use those machines for patients suspected of having COVID-19 illness. Whitney said responders were using the machines with specialized filters, which can reduce the amount of virus released. But county public health authorities recommend that first responders avoid using CPAP altogether. Redmond Fire has now discontinued the use of CPAPs for COVID-19 patients.

“It’s truly out of an abundance of caution for our people and for the community that we put it on the back shelf, unless we can confirm it was the best use for our patient,” Whitney said.

The misstep represents a classic example of how the health care system is playing catch-up in its effort to deal with the rapidly escalating pandemic, and how critical information about combating the novel coronavirus can be slow to reach those on the front lines.

The American Society of Anesthesiologists issued guidance on Feb. 23 discouraging CPAP use in COVID-19 patients — advice largely informed by experience with the SARS epidemic in 2003. Studies dating to 2003 suggest such devices can pump viruses into the air, potentially increasing the spread of a contagious disease.

During the SARS outbreak in Toronto, half of all SARS cases, including three deaths, occurred among health care workers. Some of the greatest risk arose when doctors and nurses were exposed to aerosolized virus through the use of positive airway pressure machines or other respiratory therapy devices.

The experiences from the Life Care Center of Kirkland now have doctors rethinking their strategies when faced with ventilator shortages and their advice to first responders about using CPAP machines in the field.

“In general, we’re just telling them not to use it,” said Dr. Comilla Sasson, an associate clinical professor of emergency medicine at the University of Colorado School of Medicine. “Because we are concerned about community spread, and we have to assume that anybody with respiratory distress is a COVID patient.”

And doctors even suggest those who use the devices at home should take precautions to prevent infecting others.

How CPAPs Spread The Coronavirus

Ventilators are machines that push air into and out of the lungs through tubes inserted down patients’ airways when they have trouble breathing on their own. The machines allow health care providers to fine-tune the volume of air supplied, the rate of breathing, the amount of oxygen and the pressure as needed.

Both hospital and home versions of positive airway pressure machines are much simpler devices that use high pressure to push air into the airway, generally through a face mask. CPAPs provide a continuous flow of air at a constant pressure. More advanced bilevel versions, called BiPAPs, which can be used at home or in health care facilities, push the air in, but then lower the pressure to allow the air to be exhaled.